Hawkeye Reporter

The ability to generate a patient’s blood cells in order to treat blood diseases has eluded scientists for years, but a recently awarded federal grant could help Iowa State University scientists take critical steps toward turning that possibility into reality.

 

Raquel Espin Palazon, an assistant professor of genetics, development and cell biology, leads an interdisciplinary research team examining a genetic pathway triggered when cells undergo inflammation due to injury or infection. Espin Palazon said the genetic pathway also plays an important role in the development of blood stem cells, or undifferentiated cells with the potential to develop into all human blood cell types.

 

The researchers received a 5-year, roughly $2 million grant from the National Institutes of Health to build on their work studying the pathway both in human cells and in zebrafish, and Espin Palazon said the work shows great potential to spark new advances in regenerative medicine.

Medical uses

The concept sounds simple enough.

 

Patients with blood diseases such as leukemia or anemia often need blood stem cells transplanted from a healthy donor. These healthy transplanted blood stem cells are able to repopulate the entire blood system of the patient, curing the disease. However, donors are scarce, and blood stem cell transplants are still a high-risk therapy that often leads to complications for the patient, including death.

 

Espin Palazon said it would be ideal if doctors could generate healthy blood cells from the patient for their subsequent transplantation to treat disease. Doing so would likely require the healthy cells to undergo a process turning them into stem cells, which could then be transformed into whatever cell type is needed for treatment.

 

Espin Palazon said scientists have not yet discovered all the molecular changes needed to make those transformations possible. But her previous research uncovered that an inflammatory pathway could play an important role. When cells become injured or experience infection, the pathway activates a response to help the cells fight off infection.

 

Espin Palazon discovered that blood stem cells, which are generated only in the womb before birth, activate the same pathway to generate stem cells during a key phase of development. Zeroing in on this pathway in future research could unlock the possibility of generating an endless source of a patient’s specific blood stem cells to be transplanted into the patient to cure blood disorders. Creating patient-specific blood stem cells would overcome the challenges that accompany blood stem cell transplantation, she said.

 

“We want to be able to understand at a molecular level what these inflammatory signals are doing,” Espin Palazon said. “We don’t know why they are required or what they are changing in the cell to generate blood stem cells, so we’re going to try to understand that and the timing required.”

 

Espin Palazon said it isn’t clear what connects the inflammatory pathway with stem cell production, but research has uncovered a few clues. The researchers hypothesize that the pathway preserves the stemness of cells, or the undifferentiated states that characterizes stem cells. Once the cells differentiate, they can perform only limited functions and can’t revert back into stem cells.

 

“We think inflammatory signals are important to keep the cells in the stem-cell stage so they don’t differentiate into mature cells,” she said.

 

Timing is a crucial piece of the puzzle, she said. The pathway is likely triggered at critical stages of embryonic development to create stem cells, so the scientists will have to untangle precisely when to activate the pathway to induce the desired changes in cells.

 

The researchers will study human blood cells in a lab setting as well as blood cells from zebrafish to answer their questions. Espin Palazon said zebrafish make outstanding model organisms because their embryos are transparent and develop externally, allowing for easy observation of their development under a microscope.

 

Other personnel on the research team include Clyde Campbell, adjunct assistant professor of genetics, development and cell biology; Karin Dorman, professor of statistics and genetics, development and cell biology; Jeffrey Essner, professor of genetics, development and cell biology; and Deborah French of the Children’s Hospital of Philadelphia.

Original source can be found here.